0000000000249584

AUTHOR

Luca Laurenti

showing 7 related works from this author

CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death

2011

Abstract Extracellular adenosine (ADO), generated from ATP or ADP through the concerted action of the ectoenzymes CD39 and CD73, elicits autocrine and paracrine effects mediated by type 1 purinergic receptors. We have tested whether the expression of CD39 and CD73 by chronic lymphocytic leukemia (CLL) cells activates an adenosinergic axis affecting growth and survival. By immunohistochemistry, CD39 is widely expressed in CLL lymph nodes, whereas CD73 is restricted to proliferation centers. CD73 expression is highest on Ki-67+ CLL cells, adjacent to T lymphocytes, and is further localized to perivascular areas. CD39+/CD73+ CLL cells generate ADO from ADP in a time- and concentration-dependen…

AdenosineCellular differentiationChronic lymphocytic leukemia5'-Nucleotidase; Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Antigens CD; Antineoplastic Agents Phytogenic; Apyrase; Autocrine Communication; Cell Death; Cell Differentiation; Cell Movement; Cell Survival; Etoposide; Extracellular Space; GPI-Linked Proteins; Humans; Leukemia Lymphocytic Chronic B-Cell; Paracrine Communication; Receptor Adenosine A2A; Tumor Cells Cultured; Biochemistry; Immunology; Hematology; Cell BiologyMICROENVIRONMENTCD38BiochemistryACTIVATIONAdenosine TriphosphateCell MovementPhytogenichemic and lymphatic diseasesTumor Cells CulturedChronic5'-NucleotidaseEtoposideLeukemiaCulturedCell DeathTUMOR-GROWTHApyrasePurinergic receptorCell DifferentiationHematologyLymphocyticCDTumor CellsCell biologyAdenosine DiphosphateAutocrine CommunicationLeukemiaReceptorIMMUNE SUPPRESSIONReceptor Adenosine A2ACell SurvivalImmunologyAntineoplastic AgentsAdenosinergicBiologyGPI-Linked ProteinsDAMAGE-INDUCED APOPTOSISAdenosine A2AParacrine signallingAntigens CDParacrine CommunicationmedicineHumansAntigensAutocrine signallingImmunobiologyB-CellCell BiologyDAMAGE-INDUCED APOPTOSIS; T-CELLS; IMMUNE SUPPRESSION; ZAP-70 EXPRESSION; TUMOR-GROWTH; RECEPTOR; CD73; ACTIVATION; CD38; MICROENVIRONMENTmedicine.diseaseAntineoplastic Agents PhytogenicLeukemia Lymphocytic Chronic B-CellSettore MED/15 - MALATTIE DEL SANGUET-CELLSCD73Extracellular SpaceZAP-70 EXPRESSIONCD38Blood
researchProduct

2.35 CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells

2011

Abstract Abstract 621 CD39 (ecto-nucleoside-triphosphate-diphosphohydrolase-1) and CD73 (5'-nucleotidase) are surface enzymes with extracellular catalytic sites. CD39 hydrolyses ATP/ADP to AMP, which is then converted to adenosine (ADO) by CD73. Once ADO is released in the extracellular milieu, it may re-enter the cell or engage different types of purinergic receptors, eliciting potent autocrine and paracrine cytoprotective, anti-inflammatory and immunosuppressive effects. Several lines of evidence suggest that the tumor microenvironment is marked by increased turnover of extracellular nucleotides and nucleosides, as well as by upregulation of ecto-enzymes that dismantle them. These alterat…

Cancer ResearchTumor microenvironmentbusiness.industryChronic lymphocytic leukemiaPurinergic receptorHematologymedicine.disease5'-nucleotidaseLeukemiaParacrine signallingOncologyImmunologyCancer researchExtracellularmedicineAutocrine signallingbusinessClinical Lymphoma Myeloma and Leukemia
researchProduct

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

2021

Not Available

OncologyMalechronic B cell leukemiachronic lymphocytic leukemia; ibrutinib; 4-factor score; prognosis.Datasets as TopicSeverity of Illness Indexchemistry.chemical_compoundPiperidinesRetrospective analysisMulticenter Studies as TopicChronicLeukemiaHematologyMiddle AgedPrognosisLymphocyticProgression-Free SurvivalIbrutinibFemalemedicine.medical_specialtyreal-word studyFactor scoreAntineoplastic AgentsAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival AnalysisRisk AssessmentNOibrutinibInternal medicineSeverity of illnessmedicineHumansProgression-free survivalProtein Kinase InhibitorsSurvival analysisAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelAdenineB-CellReproducibility of ResultsRetrospective cohort studyAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Analysis; Severity of Illness IndexLeukemia Lymphocytic Chronic B-CellSurvival AnalysisSettore MED/15 - MALATTIE DEL SANGUEchemistrybusinesschronic lymphocytic leukaemiaFollow-Up Studies
researchProduct

Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

2020

OncologyCancer Researchmedicine.medical_specialtySurvival risk scoreChronic lymphocytic leukemiaTreatment outcomeAntineoplastic Agentsrisk scoreNOchemistry.chemical_compoundrelapsed/refractory chronic lymphocytic leukemiaAntineoplastic Agents ImmunologicalPiperidinesibrutinibInternal medicinemedicineHumansreal-lifeMolecular Targeted TherapyChronicProtein Kinase InhibitorsFramingham Risk ScoreLeukemiachronic lymphocytic leukemia; risk score; prognosisbusiness.industryAdenineB-CellHematologymedicine.diseasePrognosisLeukemia Lymphocytic Chronic B-Cellprognostic scoreLymphocyticSurvival risk score real-life relapsed/refractory chronic lymphocytic leukemia ibrutinibLeukemiaSettore MED/15 - MALATTIE DEL SANGUEImmunologicalTreatment OutcomeOncologychemistryIbrutinibRelapsed refractorychronic lymphocytic leukemiabusiness
researchProduct

The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia.

2011

AbstractIdentification of patients at risk of early disease progression is the mainstay of tailored management in chronic lymphocytic leukemia (CLL). Although application of established biomarkers is limited by intrinsic detection/readout complexities, abnormality of κ and λ serum-free light chain ratio [sFLC (κ/λ)] was proposed as a straightforward prognosticator in CLL. By analyzing 449 therapy-naive patients, we show that an abnormal sFLC(κ/λ), along with CD38, ZAP-70, IGHV mutations, cytogenetics and stage, independently predicts treatment-free survival (TFS) but becomes prognostically irrelevant if the cumulative amount of clonal and nonclonal FLCs [sFLC(κ + λ)], a variable associated …

MaleChronic lymphocytic leukemiaMICROENVIRONMENTPROGRESSIONCD38GUIDELINESBiochemistryCohort StudiesBone MarrowLYMPHOMAMedicineAged 80 and overHematologyMiddle AgedPrognosisLeukemiaB-CELLSMonoclonalDisease ProgressionBiological MarkersFemaleIGHV@AlgorithmsAdultmedicine.medical_specialtyDISORDERSB-CELLS; CLINICAL-SIGNIFICANCE; CD38 EXPRESSION; LYMPHOMA; CLL; MICROENVIRONMENT; PROGRESSION; GUIDELINES; DISORDERS; DIAGNOSISImmunologyImmunoglobulin light chainDIAGNOSISImmunoglobulin kappa-ChainsImmunoglobulin lambda-ChainsHumansCLINICAL-SIGNIFICANCESurvival analysisAgedbusiness.industryCytogeneticsCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellSurvival AnalysisCD38 EXPRESSIONImmunologyCancer researchImmunoglobulin Light ChainsLymph NodesbusinessSettore MED/15 - Malattie del SangueBiomarkersCLLFollow-Up Studies
researchProduct

A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome

2010

Richter syndrome (RS) represents the transformation of chronic lymphocytic leukaemia (CLL) to aggressive lymphoma. Risk factors of CLL transformation to RS are only partly known. We explored the role of the host genetic background as a risk factor for RS occurrence. Forty-five single nucleotide polimorphisms (SNPs) known to be relevant for CLL prognosis were genotyped in a consecutive cohort of 331 CLL, of which 21 had transformed to RS. After correcting for multiple testing and adjusting for previously reported RS risk factors, the LRP4 rs2306029 TT variant genotype was the sole SNP independently associated with a higher risk of RS transformation (Hazard Ratio: 4·17; P = 0·001; q = 0·047).…

Chronic lymphocytic leukemiaSingle-nucleotide polymorphismAggressive lymphomaHematologyBiologymedicine.diseasehemic and lymphatic diseasesImmunologyGenotypemedicineSNPRisk factorGenotypingDiffuse large B-cell lymphomaBritish Journal of Haematology
researchProduct

Host Genetic Background and Risk of Richter Syndrome: The Genotype of LRP4 Is An Independent Predictor of Chronic Lymphocytic Leukemia Transformation…

2009

Abstract Abstract 2340 Poster Board II-317 Richter syndrome (RS) represents the transformation of chronic lymphocytic leukemia (CLL) to aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). Mechanisms and risk factors of CLL transformation to RS are known only in part. This study aimed at exploring the role of the host genetic background in RS transformation and was based on a consecutive series of 331 CLL, of which 21 had transformed to RS (all clonally related to the CLL clone). Twenty eight additional cases of clonally related RS were also collected for validation purposes. Using an educated guess approach, SNPs were selected according to the following criteria: i) re…

Oncologymedicine.medical_specialtyChronic lymphocytic leukemiaImmunologySingle-nucleotide polymorphismCell BiologyHematologyBiologymedicine.diseaseBiochemistryMinor allele frequencyInternal medicineImmunologyGenotypemedicineSNPAlleleCD5Diffuse large B-cell lymphomaBlood
researchProduct